317 related articles for article (PubMed ID: 23948546)
1. Niacin, an old drug with a new twist.
Song WL; FitzGerald GA
J Lipid Res; 2013 Oct; 54(10):2586-94. PubMed ID: 23948546
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
Pan J; Van JT; Chan E; Kesala RL; Lin M; Charles MA
Metabolism; 2002 Sep; 51(9):1120-7. PubMed ID: 12200755
[TBL] [Abstract][Full Text] [Related]
5. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
[TBL] [Abstract][Full Text] [Related]
6. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Parhofer KG
Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
[TBL] [Abstract][Full Text] [Related]
7. Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
Zeman M; Vecka M; Perlík F; Hromádka R; Staňková B; Tvrzická E; Žák A
Med Sci Monit; 2015 Jul; 21():2156-62. PubMed ID: 26210594
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
Schulz I
Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
[TBL] [Abstract][Full Text] [Related]
9. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Haynes R; Valdes-Marquez E; Hopewell JC; Chen F; Li J; Parish S; Landray MJ; Armitage J; ; ;
Clin Ther; 2019 Sep; 41(9):1767-1777. PubMed ID: 31447131
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
McKenney JM
Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
[TBL] [Abstract][Full Text] [Related]
11. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
12. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
[TBL] [Abstract][Full Text] [Related]
13. The facts behind niacin.
Hochholzer W; Berg DD; Giugliano RP
Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
15. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
17. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Le NA; Jin R; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2013 Aug; 2(4):e000037. PubMed ID: 23926117
[TBL] [Abstract][Full Text] [Related]
18. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
Vosper H
Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
[TBL] [Abstract][Full Text] [Related]
19. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
Keenan JM
J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578
[TBL] [Abstract][Full Text] [Related]
20. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]